Viome Life Sciences, a Bellevue, WA-based digital health company, raised $67M in funding.
The round was led by Bold Capital Group, with participation from existing investors Khosla Ventures, West River Group, Glico, Ocgrow Ventures, and Physician Partners.
The company intends to use the funds to support the continuous development of its product pipeline, including the Oral Health Intelligence Test, early detection diagnostic tests for chronic diseases, and cancers.
Led by Founder & CEO Naveen Jain, Viome Life Sciences is a biotechnology company launched in 2016 to address the epidemic of chronic diseases, cancer, and aging. The company developed a suite of innovative diagnostic tools to empower over half a million users to test, not guess, and to receive actionable insights to empower each of us to live a longer and healthier life. Viome’s proprietary approach combines novel mRNA research and FDA-backed technology to analyze epigenetic biomarkers to deliver comprehensive, AI-driven health insights to shape a healthy lifespan.
The latest round follows the launch of Viome’s first CancerDetect™ test for oral & throat cancers. This at-home early diagnostic tool can detect early biomarkers associated with oral and throat cancer with high rates of specificity and sensitivity. CancerDetect™ is powered by Viome’s proprietary mRNA sequencing technology and AI-powered platform, which the FDA awarded Breakthrough Device Designation status in May of 2021.
In the coming months, Viome will leverage this funding to debut a suite of new wellness and diagnostic tests specifically targeting the oral microbiome. Building upon the success of CancerDetect™ for oral and throat cancer, the company is also utilizing this same technology to power early detection for additional hard-to-detect cancers and GI disorders such as IBD.